Swiss perspectives in 10 languages

Pharma obesity market: Roche seeks deals to challenge Lilly and Novo

Picture of Roche headquarters in Basel
The Swiss drugmaker said on Tuesday that it’s on the hunt for additional biotech partners to help it challenge weight-loss leaders Novo Nordisk A/S and Eli Lilly & Co. © Keystone / Georgios Kefalas

Roche Holding AG isn’t done making moves in the obesity market after last month’s agreement to buy Carmot Therapeutics Inc. for as much as $3.1 billion (CHF2.64 billion).

The Swiss drugmaker said on Tuesday that it’s on the hunt for additional biotech partners to help it challenge weight-loss leaders Novo Nordisk A/S and Eli Lilly & Co. Roche is looking for new ways of adjusting metabolism that could ultimately be combined with treatments it’s gaining in the Carmot deal.

“This is opening up a whole new vista for us,” James Sabry, Roche’s head of partnering, said in an interview on the sidelines of the JPMorgan Healthcare Conference in San Francisco.

More

Carmot was one in a flurry of recent deals Roche has made to bolster its pipeline. The company is also interested in oncology, neurology and ophthalmology as well as cardiovascular medicine, Sabry said. 

While many companies are trying to break into the hot weight-loss market, Sabry said Roche is one of only a handful of suitors with the size and global reach to run the large, costly trials necessary to bring new drugs to market. Marketing obesity medicines is also more complicated than other areas like cancer because drugmakers need to deal with primary-care doctors instead of a few specialised treatment centres, he said.

More

“When we’re trying to get a deal done, we find more competitors in oncology,” he said. “You’d think everyone must be competing with you for metabolism drugs, but it’s not that way.”

Roche was one of the first pharmaceutical companies to work on an experimental drug in the GLP-1 class, a category that includes Novo’s Wegovy and Lilly’s Zepbound. But it halted development more than a decade ago after patients dropped out of a study due to side effects such as nausea.

©2024 Bloomberg L.P.

News

Two Rothornbahn gondolas cross each other on Lenzerheide on Friday, April 3, 2009.

More

Swiss cable car activity rose in winter 2023-2024

This content was published on In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.

Read more: Swiss cable car activity rose in winter 2023-2024
flooding Rhine

More

Rhine flooding: Swiss to invest CHF1 billion with Austria

This content was published on As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.

Read more: Rhine flooding: Swiss to invest CHF1 billion with Austria

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR